Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX6UYN)

• Drug Name: (+)-BUTACLAMOL Drug Info
• Synonyms: d-Butaclamol; (+)-Butaclamol; BUTACLAMOL; CHEMBL8514; 56245-67-1; 1H-Benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 2,3,4,4a,8,9,13b,14-octahydro-3-(1,1-dimethylethyl)-, (3S-(3-alpha,4a-alpha,13b-beta))-; (+/-)-Butaclamol hydrochloride; BUTACLAMOL,d-; AC1L1XRQ; BUTACLAMOL,(+); GTPL62; BUTACLAMOL, (-); Biomol-NT_000018; Lopac0_000475; Lopac0_000187; SCHEMBL122821; BPBio1_001177; ZZJYIKPMDIWRSN-HWBMXIPRSA-N; CHEBI:109533; HMS2089C08; ZINC2008410; PDSP2_000547; PDSP2_001512; BDBM50008735; CCG-204282; NCGC00162085-04

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 37459
  ChEBI ID: CHEBI:109533
  CAS Number: CAS 56245-67-1
  TTD Drug ID: DMX6UYN

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[6]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[7]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[7]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[8]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[9]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[10]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[11]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[12]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[13]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[13]

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[14]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[7]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[15]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[16]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[17]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[18]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[19]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[20]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[21]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[22]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[23]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[24]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[25]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[26]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[27]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[28]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[2]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[29]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[26]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[26]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[30]
Haloperidol	DM96SE0	Delirium		Approved	[31]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[32]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[33]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[34]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[35]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[36]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[37]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[38]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[39]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[2]
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[3]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[4]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Inhibitor	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 62).
• [2] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [3] 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem. 2000 May 18;43(10):2079-81.
• [4] Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
• [5] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [6] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [9] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [15] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [16] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [17] Clinical pipeline report, company report or official report of Lundbeck.
• [18] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [19] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [20] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [21] Clinical pipeline report, company report or official report of Lundbeck
• [22] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [23] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [24] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [25] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [26] 2011 Pipeline of Can-Fite BioPharm.
• [27] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [28] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [29] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [30] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [31] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [32] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [33] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [34] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [36] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [37] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [38] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [39] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.